These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2816289)

  • 1. Plasma C3c changes in myasthenia gravis patients receiving high-dose intravenous immunoglobulin during crisis.
    Kamolvarin N; Hemachudha T; Ongpipattanakul B; Phanuphak P; Viddayakorn P; Sueblinvong T
    Acta Neurol Scand; 1989 Oct; 80(4):324-6. PubMed ID: 2816289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma exchange in myasthenia gravis: changes in serum complement and immunoglobulins.
    Thorlacius S; Mollnes TE; Garred P; Aarli JA; Matre R; Tönder O; Halvorsen K
    Acta Neurol Scand; 1988 Sep; 78(3):221-7. PubMed ID: 3227807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose intravenous immunoglobulin for myasthenia gravis.
    Sakano T; Hamasaki T; Shimizu H; Harada Y; Ueda K
    Hiroshima J Med Sci; 1988 Mar; 37(1):7-9. PubMed ID: 3410736
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis.
    Arsura EL; Bick A; Brunner NG; Grob D
    Am J Med Sci; 1988 May; 295(5):438-43. PubMed ID: 3376987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose intravenous immunoglobulin in myasthenia gravis.
    Evoli A; Palmisani MT; Bartoccioni E; Padua L; Tonali P
    Ital J Neurol Sci; 1993 Apr; 14(3):233-7. PubMed ID: 8314677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoadsorption plasmapheresis for severe generalised myasthenia gravis.
    Ichikawa M; Koh CS; Hata Y; Tohyama M; Tsuno T; Komiyama A
    Arch Dis Child; 1993 Aug; 69(2):236-8. PubMed ID: 8215529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis.
    Tüzün E; Saini SS; Ghosh S; Rowin J; Meriggioli MN; Christadoss P
    Neuromuscul Disord; 2006 Feb; 16(2):137-43. PubMed ID: 16427283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma exchange in myasthenia gravis complicated with complement activation and urticarial reactions using fresh-frozen plasma as replacement solution.
    Rosenkvist J; Berkowicz A; Holsøe E; Sørensen H; Taaning E
    Vox Sang; 1984; 46(1):13-8. PubMed ID: 6702139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia gravis: passive transfer from man to mouse.
    Toyka KV; Brachman DB; Pestronk A; Kao I
    Science; 1975 Oct; 190(4212):397-9. PubMed ID: 1179220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.
    Toyka KV; Drachman DB; Griffin DE; Pestronk A; Winkelstein JA; Fishbeck KH; Kao I
    N Engl J Med; 1977 Jan; 296(3):125-31. PubMed ID: 831074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose intravenous gammaglobulin for myasthenia gravis.
    Fateh-Moghadam A; Wick M; Besinger U; Geursen RG
    Lancet; 1984 Apr; 1(8381):848-9. PubMed ID: 6200741
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of myasthenia gravis by immunoadsorption of plasma.
    Grob D; Simpson D; Mitsumoto H; Hoch B; Mokhtarian F; Bender A; Greenberg M; Koo A; Nakayama S
    Neurology; 1995 Feb; 45(2):338-44. PubMed ID: 7854536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoadsorption therapy and complement activation.
    Pták J; Lochman J
    Transfus Apher Sci; 2005 Jun; 32(3):263-7. PubMed ID: 15944112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose intravenous immunoglobulin in the management of myasthenia gravis.
    Bonaventura I; Ponseti J; Arnau E; Matias-Guiu J; Codina Puiggros A
    Arch Intern Med; 1987 Feb; 147(2):207, 211. PubMed ID: 3813729
    [No Abstract]   [Full Text] [Related]  

  • 16. Correlation of C3 level with severity of generalized myasthenia gravis.
    Liu A; Lin H; Liu Y; Cao X; Wang X; Li Z
    Muscle Nerve; 2009 Nov; 40(5):801-8. PubMed ID: 19670317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma C3c in immune-mediated neurological diseases: a preliminary report.
    Kamolvarin N; Hemachudha T; Ongpipattanakul B; Phanthumchinda K; Sueblinvong T
    Acta Neurol Scand; 1991 Jun; 83(6):382-7. PubMed ID: 1716038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2003; (2):CD002277. PubMed ID: 12804431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent developments in high-dose immunoglobulin therapy: therapeutic plasma exchange, autoimmune diseases].
    Kalden JR; Schranz W; Lösch G; Krapf F; Bartels O
    Beitr Infusionther Klin Ernahr; 1982; 9():48-59. PubMed ID: 6216881
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of Plasma Exchange Combined with Immunoglobulin Therapy on Consciousness, Immune Function, and Prognosis in Patients with Myasthenia Gravis Crisis: A Prospective Randomized Test.
    Peng X; Xie XB; Tan H; Zhang D; Jiang BT; Liu J; Li S; Chen YR; Xie TY
    Comput Math Methods Med; 2022; 2022():7796833. PubMed ID: 35813442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.